Explore the latest updates on using immunotherapy for the treatment of patients with advanced bladder cancer with these downloadable slides presented at our symposium held at the ESMO Immuno Oncology Congress 2017.
Dec 11, 2017
Dec 11, 2018
- Aristotle Bamias, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece
The biological basis for checkpoint inhibition in cancer treatment
- Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France
A giant leap in the treatment options for advanced bladder cancer
- Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Conclusions and prIME Points™
This educational activity is specifically designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with urothelial cancers.
After successful completion of this educational activity, participants should be able to:
- Describe the molecular basis for immunotherapy in cancers, including the function of immune checkpoints in the presence and absence of cancers
- Examine the current evidence of the role of biomarkers and how to apply them in clinical practice
- Explain the unique patterns of response to immunotherapy
- Identify immune-related adverse events and strategies to manage them
- Examine clinical trial findings for immune checkpoint inhibitors in advanced urothelial cancers
- Describe the rationale for combination therapies of immunotherapeutic agents with each other, with chemotherapy, and with targeted agents
This educational activity is supported by a grant from F. Hoffmann-La Roche Ltd.
Enduring Material From a Certified Activity
This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Bamias has disclosed that he received consulting fees from Bristol-Myers Squibb, Merck Sharp & Dohme, and Roche. He has also received fees for non-CME services received directly from commercial interest or their agents from Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Loriot has disclosed that he received consulting fees from Astellas, AstraZeneca, Janssen, Merck Sharp & Dohme, Pfizer, Roche, and Seattle Genetics. He has also performed contracted research or received research support from Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Powles has disclosed that he received consulting fees from AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. He has also performed contracted research or received research support from AstraZeneca and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – contracted research for Amgen and Bayer
- Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.